Thus, two structurally distinct FAK inhibitors, VS-4718 and VS-6063, preferentially target CSCs in breast cancer cell lines indicating that FAK kinase activity is important for the maintenance of CSCs. The gene discussed is PTK2; the disease is breast carcinoma.